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introDuCtion
Radiotherapy aims to achieve tumour control by killing 
cancer cells while simultaneously sparing healthy tissues. 
However, cancer cells and healthy cells share similar 
characteristics that limit both the sensitivity of detection 
and therapeutic ratio of radiation response in tumour 
and healthy tissue. Tumour-targeted nanoparticles have 
potential to overcome these fundamental limitations, first 
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aBstraCt
A multi-disciplinary cooperative for nanoparticle-enhanced radiotherapy (NERT) has been formed to review the current 
status of the field and identify key stages towards translation. Supported by the Colorectal Cancer Healthcare Tech-
nologies Cooperative, the cooperative comprises a diverse cohort of key contributors along the translation pathway 
including academics of physics, cancer and radio-biology, chemistry, nanotechnology and clinical trials, clinicians, 
manufacturers, industry, standards laboratories, policy makers and patients. Our aim was to leverage our combined 
expertise to devise solutions towards a roadmap for translation and commercialisation of NERT, in order to focus 
research in the direction of clinical implementation, and streamline the critical pathway from basic science to the clinic. 
A recent meeting of the group identified barriers to and strategies for accelerated clinical translation. This commen-
tary reports the cooperative’s recommendations. Particular emphasis was given to more standardised and cohesive 
research methods, models and outputs, and reprioritised research drivers including patient quality of life following 
treatment. Nanoparticle design criteria were outlined to incorporate scalability of manufacture, understanding and 
optimisation of biological mechanisms of enhancement and in vivo fate of nanoparticles, as well as existing design 
criteria for physical and chemical enhancement. In addition, the group aims to establish a long-term and widespread 
international community to disseminate key findings and create a much-needed cohesive body of evidence necessary 
for commercial and clinical translation.
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demonstrated in the pioneering study by Hainfeld et al,1 in 
which gold nanoparticle-based radiation therapy was used to 
enhance the therapeutic ratio in mice. A plethora of in vitro and 
in vivo studies demonstrate enhancement factors on the order of 
10–100% at clinically feasible concentrations.2 Despite the prom-
ising experimental results presented in the literature there has 
been limited clinical translation of this concept, with only two 
metal-based nanoformulations currently in NERT clinical trials; 
gadolinium-based polysiloxanes theranostic particles (AGuIX, 
NH TherAguix SAS) and hafnium oxide particles (Nanobiotix 
SA). Lack of translation is largely due to an incohesive set of 
experimental parameters (unrelated broad spectra of cell lines, 
nanoparticle properties, nanoparticle coating, radiation charac-
teristics) – each of which impact on radiation enhancement, and 
also poor consideration of in vivo factors. Our cooperative has 
instead approached the problem from a clinical and commercial 
angle early on to outline a roadmap to translation that is opti-
mised, streamlined and accelerated. Here we highlight priority 
research development areas required for translation.
unDerstanDinG oF unDerLyinG meChanisms 
oF BioLoGiCaL enhanCement
Understanding of mechanisms driving NERT will inform the 
correct experimental read-outs to enable comparison and mech-
anism-driven optimisation of nanosolutions. Monte Carlo simu-
lations can be used to calculate the physical dose enhancement 
on the microscale stemming from photoelectrons and Auger 
electrons (the probability of these interactions increasing with 
atomic number of material, the original reason for using gold).3,4 
However, physical models underestimate the observed biological 
enhancement in cellular systems.5 Alternative mechanisms have 
been suggested including nanoparticle-induced cellular oxidative 
stress and enhanced production of reactive oxygen species, and 
modification of the cell cycle to radiosensitive phases.6 However, 
there is still no consensus nor significant evidence regarding the 
fundamental science governing these processes, and additional 
mechanisms may yet be at play. Therefore, mechanism discovery 
through introduction of more sophisticated methodologies not 
currently performed in this field such as genomics or proteomics 
is required.
Nanoparticle design strategies
It is currently difficult to confirm any relative advantages between 
different nanoparticle-based therapeutic strategies because 
nanoparticle design parameters and corresponding read-outs 
are highly varied throughout the field, and commonly focus on 
one mechanistic optimisation (e.g. physical dose enhancement). 
Nanoparticle design should be guided by all major needs of the 
nanosystem, including:
•	 Factors that affect in vivo radiation enhancement including; 
protein corona changes in vivo, colloidal stability and 
aggregation, cellular and nuclear localisation, and toxicity 
profile and clearance pathway
•	 High circulation time in order to increase passive uptake
•	 3D penetration to ensure required tumour distribution
•	 Scalability of manufacture
•	 Environmental impact of the nanoformulation
•	 Multifunctionality for imaging and drug delivery options
Cohesive and representative pre-clinical testing 
strategies
Pre-clinical NERT studies reported in the literature are currently 
diverse in models, methodologies and outcome reporting.
(a) Cohesive methodologies
Implementation of more cohesive methodologies should be 
prioritised in order to maintain consistency and comparability 
across this multi-disciplinary community. Results are reported in 
wide-ranging journals spanning different fields, making consis-
tency in experimental approach more challenging. This high-
lights the importance of multidisciplinary research to address this 
issue. More clarity in terminology when referring to nanoparticle 
dosage, and clear reporting of cellular concentrations and bio-lo-
calisation will add value to results. Clearly expressed radiation 
parameters are essential to understand the impact of radiation 
on mechanism and enhancement. The formal introduction of 
metrics and standardisation to include the dual effect of nanopar-
ticles alongside radiation, seeking guidance from standards labo-
ratories such as the National Physical Laboratory, and both the 
European and US Nanotechnology Characterisation Laborato-
ries, could provide researchers with a more consistent basis upon 
which to measure and report treatment efficacy.
(b) Standardised set of outcome measures
Unlike pharmaceutical drugs which use IC50 and EC50 as stan-
dardised measurements for efficacy and potency respectively, 
NERT does not have a standard to define efficacy. The underlying 
mechanisms must be understood in order to identify the correct 
read-outs to compare different nanoformulations. The classifica-
tion of nanoparticles in this application – drug or medical device 
– will determine which testing standards are needed. Researchers 
should engage with authorities such as the MHRA to assist in 
defining nanoformulations and shape regulatory thinking, with 
reporting of enhancement following international standardiza-
tion practice7,8 making it easier to report to regulatory bodies.
(c) Representative models
Models should be representative of intra- and inter-tumour 
heterogeneity. Drug resistant models should be developed to 
represent patients of unmet need. For reliable precision medi-
cine, increased use of phenotypic screening in patient derived 
models9 should also be implemented to allow researchers to test 
for patients who may derive significant benefit. Models should 
better represent in vivo factors, including human serum proteins 
and their impact on the protein corona10 and downstream 
biodistribution and aggregative instability.
Nanoparticle delivery strategies
The optimal delivery mechanism would give the greatest differ-
ential uptake between tumour and healthy tissue, and lowest 
toxicity. Passive uptake mechanisms through intravenous injec-
tion and direct intratumoural injection have been implemented 
in current clinical trials of AGuIX11 and Nanobiotix12 particles 
respectively; active targeting has so far been resisted by commer-
cial partners due to the manufacturing difficulty associated with 
personalised coating, and poses practical challenges in terms of 
keeping the integrity of the functional coating once introduced 
into an in vivo system, with increased size of nanoparticles due 
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to the hydrodynamic radius of targeting ligands resulting in 
issues with tumour penetration.13 There are also a lack of suit-
able biomarkers and imaging strategies for defining optimal 
uptake and bioavailability of targeted nanoparticles. Therefore, 
it was suggested that research is focussed on passive uptake via 
the enhanced permeability and retention (EPR) effect. There is 
scope to further optimise nanoparticle size/shape for EPR, and 
to exploit the interplay between radiation-induced biological/
vascular damage and nanoparticle accumulation.14 Double local-
isation using focussed radiation may negate less precise targeting 
offered by the EPR effect.
DisCussion
Implementing the combined perspectives from manufacturers, 
clinicians and patients allows researchers to develop NERT prod-
ucts with more understanding of the efficacy criteria as defined 
by the priorities of those manufacturing, delivering and receiving 
treatment. Viewpoints from each group follow.
Manufacturer perspectives
Translation and integration of NERT technologies relies on 
a consistently homogenous and reproducible end-product. 
However, the majority of nanoparticles used in preclinical 
studies implement small batch synthesis strategies, making 
scale-up for larger quantities impossible in some instances.15 It 
follows that large quantity scale-up should be prioritised during 
the nanoparticle design stage, with the same tools being used at 
discovery and scale-up stages. Contract manufacturing organi-
sations should be included during the initial design stages, and 
laboratory plans and procedures should be parallelised to the 
manufacturer laboratory.
Clinical perspectives
Future use of this concept will particularly benefit tumours 
where radiotherapy tumour dose is restricted by surrounding 
normal tissue tolerances, tumours that are targetable and those 
where current treatment yields unsatisfactory results. In line with 
recent guidelines to accelerate drug-radiation development,16 
NERT becomes a clinically viable option if it:
•	 displays lower toxicity than alternatives for similar efficacy 
(including dose de-escalation)
•	 displays greater efficacy than current standard of care 
(including nanoparticle-mediated dose escalation)
•	 can replace surgery to improve quality of life
•	 can guide therapies (multifunctional solution: optical 
fluorescence for intraoperative guidance, MRI or CT contrast 
to guide radiotherapy)
•	 offers a pathological response
Implementation of NERT will require modifications to clin-
ical workflow, and a number of research questions remain to 
be answered which currently act as barriers to clinical transla-
tion. The mode of nanoparticle introduction, tumour targeting 
strategies, frequency and timing of nanoparticle injection prior 
to irradiation, and biological fate of the nanoparticles must be 
considered. Platforms to quantify nanoparticle concentration 
distribution are required, profiting from theranostic nanoparticle 
solutions with imaging capability. It is imperative that clinical 
trials are designed to consider the extent to which nanoparticle 
concentration in both tumour and healthy tissue has an effect 
on radiation dosimetry and develop strategies to incorporate 
the expected dose distribution changes into the treatment plan-
ning process. This may be particularly important during charged 
particle therapy, where density changes induced by metallic 
nanoparticles can have a significant impact on dose distribution 
and Bragg peak characteristics.17
Patient perspectives
Patients and consumer groups should be involved from the 
clinical trial concept stage onwards for a clear understanding of 
patient priorities and what strategies they accept. Outcomes of 
trials must include patient reported outcome measures as well 
as conventional efficacy and toxicity measures. The physical 
and psychological impact of treatment must be considered, the 
latter having longer lasting implications; shifting the focus from 
prevention of death, to preparation for life.
ConCLusion
NERT demonstrates great potential to enhance the therapeutic 
ratio in radiotherapy for improved patient outcomes and reduced 
side effects. In order to accelerate clinical translation for patient 
benefit, barriers to translation must be identified in the first 
instance, and research driven to overcome those barriers. The 
cooperative recommends that research is prioritised to themes 
that are on the critical path to translation, including nanoparticle 
design driven by manufacturer scalability, in vivo fate and patient 
priorities, as well as NERT enhancement mechanisms. Mecha-
nism discovery of NERT and standardisation of appropriate 
experimental methods is required to enable meaningful compar-
ison of nanoparticle systems throughout the diverse research 
community. Towards this aim, development of a database plat-
form to deposit this wide-ranging data would make strides 
towards accelerating clinical translation. The cooperative’s future 
goal is to establish a widespread community representative of all 
required groups to create a cohesive, clinically and industrially 
aligned body of evidence required for translation.
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